Artificial intelligence-based prognostic model accurately predicts the survival of patients with diffuse large B-cell lymphomas: analysis of a large cohort in China.

Journal: BMC cancer
PMID: 38773392

Abstract

BACKGROUND: Diffuse large B-cell lymphomas (DLBCLs) display high molecular heterogeneity, but the International Prognostic Index (IPI) considers only clinical indicators and has not been updated to include molecular data. Therefore, we developed a widely applicable novel scoring system with molecular indicators screened by artificial intelligence (AI) that achieves accurate prognostic stratification and promotes individualized treatments.

Authors

  • Huilin Peng
    Department of Lymphatic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
  • Mengmeng Su
    State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, 100875, China.
  • Xiang Guo
    State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, P. R. China. guoxiang@sysucc.org.cn.
  • Liang Shi
    Department of Andrology,Drum Tower Clinical College of Nanjing Medical University，Nanjing, jiangsu 210008,China.
  • Tao Lei
    College of Electronical and Information Engineering, Shaanxi University of Science and Technology, Xi'an, China.
  • Haifeng Yu
    Anshan Institute for Food and Drug Control, Anshan 114006, China.
  • Jieyu Xu
    Department of Lymphatic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
  • Xiaohua Pan
    Binjiang Institute of Zhejiang University, Hangzhou, Zhejiang, 310053, China. panxh@zju-bj.com.
  • Xi Chen
    Department of Critical care medicine, Shenzhen Hospital, Southern Medical University, Guangdong, Shenzhen, China.

Keywords

External Resources

Popular Topics
Recent Journals